💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ritlecitinib

CHEMBL4085457 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
285.3 g/mol
LogP
2.1
Phase
4

Ritlecitinib is an irreversible covalent inhibitor of JAK3 and the TEC family of kinases (including ITK, RLK, BTK, BMX, and TXK) that blocks signaling from multiple pro-inflammatory cytokines through the JAK3/STAT pathway and T-cell receptor signaling through the TEC kinase pathway. It is approved for the treatment of alopecia areata in adults and adolescents, and is under investigation in other immune-mediated inflammatory conditions.

น้ำหนักโมเลกุล

285.3400 g/mol

LogP

2.10

TPSA

73.90 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Rheumatoid Arthritis

กลไกการออกฤทธิ์

Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C

                

                

                
                

                    
InChI

                    
InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H19N5O

                    

                    
                    

                        
HBD / HBA

                        
2 / 4

                    

                    
                    

                        
พันธะที่หมุนได้

                        
3

                    

                    
                    
                    

                        
อะตอมหนัก

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Ritlecitinib is an irreversible covalent inhibitor of JAK3 and the TEC family of kinases (including ITK, RLK, BTK, BMX, and TXK) that blocks signaling from multiple pro-inflammatory cytokines through the JAK3/STAT pathway and T-cell receptor signaling through the TEC kinase pathway. It is approved for the treatment of alopecia areata in adults and adolescents, and is under investigation in other immune-mediated inflammatory conditions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ritlecitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4085457.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 118115473.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.